Veraxa Biotech AG reports that shareholders at the 24 July 2026 Extraordinary General Meeting approved all Board proposals, with more than 99.94% of votes cast on 102,102,301 voting shares, representing 72.20% of share capital. The amendments are intended to support long-term growth and strategic flexibility.
The Articles state share capital of CHF 1,248,634 + 50/453, divided into 141,407,813 registered shares with a par value of CHF 100/11,325 each. New authorizations add conditional share capital for equity-linked instruments, merger-related options, and employee and advisory plans, plus a capital band permitting issuance of up to 70,662,564 additional shares until 31 December 2030, in defined cases with excluded or limited subscription rights.
Governance changes include increasing the maximum Board size from five to seven and detailed rules on compensation approval, stock-based incentives and outside mandates. Veraxa also highlighted progress on its BiTAC T-cell engager program and named Carl von Halem interim CFO and Christoph Erkel, Ph.D. as Chief Scientific Officer.